PTC Therapeutics
PTCT
115 hedge funds and large institutions have $310M invested in PTC Therapeutics in 2017 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 38 increasing their positions, 34 reducing their positions, and 27 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 34
7.67% more ownership
Funds ownership: 83.56% → 91.23% (+7.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 27
1% less capital invested
Capital invested by funds: $313M → $310M (-$2.68M)
9% less call options, than puts
Call options by funds: $15.1M | Put options by funds: $16.5M
7% less funds holding
Funds holding: 123 → 115 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$38.8M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$18.2M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$17.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$15.8M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.3M |
| 2 |
Millennium Management
New York
|
-$9.53M |
| 3 |
TAM
Tocqueville Asset Management
New York
|
-$8.84M |
| 4 |
JP Morgan Chase
New York
|
-$6.76M |
| 5 |
SA
Sicart Associates
New York
|
-$4.7M |
PTCT Hedge Fund Activity: Q1 2017 in Review
115 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2017, worth a combined $310M — down 0.86% from $313M a quarter earlier.
Fund positioning in PTCT was balanced in Q1 2017: 27 funds opened new positions, 27 closed out, 38 added to existing stakes and 34 trimmed.
The largest buyer was BlackRock, adding an estimated $38.8M. The largest seller was Wellington Management Group, cutting an estimated $30.3M.
- 115 institutional investors held PTC Therapeutics (PTCT) as of Q1 2017, down from 123 in Q4 2016.
- Funds reported $310M of PTC Therapeutics stock for Q1 2017, down 0.86% quarter-over-quarter.
- 27 funds opened new PTC Therapeutics positions in Q1 2017 and 27 closed out, a net change of 0 holders.
- The largest PTC Therapeutics buyer in Q1 2017 was BlackRock, an estimated $38.8M added.
- The largest PTC Therapeutics seller in Q1 2017 was Wellington Management Group, an estimated $30.3M sold.
Based on aggregated 13F filings for Q1 2017.